ZRG Partners has announced their third-quarter findings for the Global Life Sciences Hiring Index. Q2 2018 activity posted a second straight all-time high due to continued economic strength and sector resurgences.
ZRG European President and Global Practice Head of Life Sciences, Adam El Din commented, “US FDA is amending its 510(k) third-party review program 3PRO to reduce the need for agency re-reviews of these submissions and market entry delays. As part of the 3PRO overhaul, the FDA will adjust its list of eligible devices to focus more on lower-risk, less complex products. By 2021, the FDA wants 85% of 3PRO-reviewed 510(k) submissions to go through without the need for agency re-review.”
David Fortier, Global Head, Life Sciences Practice added, “The long-sustained historical highs in hiring activity and ultra-competitiveness for top executives, scientists and physicians continue to put pressure on our clients’ ability to fully execute their plans. It has never been easier for passive candidates to be approached and resultingly, they are contacted several times per week. This ease of approach has made it more difficult for great opportunities to stand apart from the rest of the field and has led to more confidence among workers and lower willingness to engage in a process without uncertainty or another strong catalyst in their current role.”